(5R)-1-(4-chlorobutyl)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-pyrrolidin-2-one | 540721-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (5R)-1-(4-chlorobutyl)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-pyrrolidin-2-one
• 英文别名: (5R)-1-(4-chlorobutyl)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]pyrrolidin-2-one；(5R)-1-(4-chlorobutyl)-5-[(E)-3-hydroxy-4-phenylbut-1-enyl]pyrrolidin-2-one
• CAS: 540721-64-0
• 化学式: C₁₈H₂₄ClNO₂
• 分子量: 321.847
• InChiKey: RPGOCZPACVXLIO-FNPGKKEOSA-N

物化性质

• 沸点：
  505.7±50.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5R)-1-(4-chlorobutyl)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-pyrrolidin-2-one 在 lithium hydroxide 、 sodium methylate 、 四丁基碘化铵 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[(4-{(2R)-2-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl}butyl)thio]propanoic acid
  参考文献：
  名称：

  Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

  摘要：

  Analogues of PGE(2) wherein the hydroxycyclopentanone ring has been replaced by a lactam have been prepared and evaluated as ligands for the EP4 receptor. An optimized compound (19a) shows high potency and agonist efficacy at the EP4 receptor and is highly selective over the other seven known prostaglandin receptors. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00042-8
• 作为产物：
  描述：

  (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 在 sodium tetrahydroborate 、 sodium hydride 、 戴斯-马丁氧化剂 、 氟化氢吡啶 作用下， 以 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (5R)-1-(4-chlorobutyl)-5-[(1E)-3-hydroxy-4-phenylbut-1-enyl]-pyrrolidin-2-one
  参考文献：
  名称：

  Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

  摘要：

  Analogues of PGE(2) wherein the hydroxycyclopentanone ring has been replaced by a lactam have been prepared and evaluated as ligands for the EP4 receptor. An optimized compound (19a) shows high potency and agonist efficacy at the EP4 receptor and is highly selective over the other seven known prostaglandin receptors. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00042-8

文献信息

• Ep4 receptor agonist, compositions and methods thereof
  申请人：——

  公开号：US20040204590A1

  公开（公告）日：2004-10-14

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  这项发明涉及前列腺素E2受体EP4亚型的有效选择性激动剂，其在治疗青光眼和其他与患者眼内高眼压相关的疾病中的使用或配方。该发明还涉及利用本发明的化合物介导成骨细胞和破骨细胞的骨建模和重塑过程。
• 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
  申请人：Billot Xavier

  公开号：US20050239872A1

  公开（公告）日：2005-10-27

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors of formula (1), their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of the patient.

  本发明涉及公式（1）的EP4型前列腺素E2受体的强效选择性激动剂，以及它们在治疗青光眼和其他与患者眼内压升高相关的疾病中的使用或配制。
• EP4 receptor agonist, compositions and methods thereof
  申请人：Billot Xavier

  公开号：US20090258918A1

  公开（公告）日：2009-10-15

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient.

  本发明涉及到前列腺素E2受体的EP4亚型的有效选择性激动剂，它们的使用或其制剂在治疗青光眼和其他与患者眼内压升高相关的疾病中应用。
• EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF
  申请人：Billot Xavier

  公开号：US20130317013A1

  公开（公告）日：2013-11-28

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient.

  本发明涉及到PGE2受体EP4亚型的强效选择性激动剂，以及它们在治疗青光眼和其他与患者眼内压升高有关的疾病中的使用或制剂。
• 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA
  申请人：Merck Frosst Canada Ltd.

  公开号：EP1513589B1

  公开（公告）日：2010-11-10